TICKERNERD
Menu
PGENPGENHealthcare · Biotechnology

PGEN Stock Forecast: Precigen, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$7.78
−1.14% on the day

The 3 Wall Street analysts covering Precigen, Inc. hold a median 12-month price target of $15 — +86.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.8B
Ticker Nerd rank
83 / 100
Median analyst target
$15
Analysts covering
3
Revenue$55.0M+6322.7% y/y
Operating income$22.6M
Net income$20.1M
Free cash flow−$18.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+13.6%
1M
+15.3%
YTD
+86.1%
1Y
+104.7%
From 52W high
−1.1%
From 52W low
+151.0%
$3.10
$7.87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Precigen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
100
Momentum
99
Value
95
Growth
72
Volatility
59
Quality
50
Accruals
48
Size
31
Issuance
8

Revisions (100): Analysts have, on balance, been raising their forecasts.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26PGENHigh $18Median $15Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $11Median $15High $18

The green dot is the last close — the median target sits +86.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026HC Wainwright & Co.MaintainsBuy$14 → $18
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$14
28 May 2026HC Wainwright & Co.MaintainsBuy—
28 May 2026HC Wainwright & Co.MaintainsBuy$11 → $14
14 May 2026CitizensMaintainsMarket Outperform—
14 May 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026CitizensMaintainsMarket Outperform—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
19 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025JP MorganUpgradeNeutral—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
12 June 2025JMP SecuritiesReiteratesMarket Outperform—
15 May 2025Cantor FitzgeraldReiteratesOverweight—
20 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Precigen, Inc. returned +104.7% against +16.3% for the S&P 500, dividends included.

PGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26PGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Precigen, Inc. (PGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.7×

Cheaper than 90% of US stocks

Price / sales
32.5×

Cheaper than 7% of US stocks

Price / book
63.8×

Cheaper than 2% of US stocks

EV / EBITDA
−80.5×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
6322.7%

Higher than 99% of US stocks

Earnings growth (YoY)
6322.7%

Higher than 99% of US stocks

Gross margin
94.9%

Higher than 98% of US stocks

Operating margin
41.2%

Higher than 92% of US stocks

Net margin
−184.0%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−837.1%

Higher than 2% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Precigen, Inc. (PGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Precigen, Inc. has a market value of $2.8B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $85.7M. The latest quarter grew 6322.7% year on year.

  • Net income over the same four quarters: −$157.7M, a −184.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$115.2M.

  • Precigen, Inc. spent $1.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 358.0M.

  • Trailing P/E: −5.7×; forward P/E: −35.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Precigen, Inc. employs 160 people — $536K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

PGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PGENPrecigen, Inc.$2.8B
83
ATAIAtai Beckley, Inc.$2.7B
—
IMNMImmunome, Inc.$2.6B
33
BRVEBraveheart Bio, Inc.$2.6B
0
IRONDisc Medicine, Inc.$2.6B
38
NAMSNewAmsterdam Pharma Co. NV$2.6B
39
NRIXNurix Therapeutics, Inc.$2.6B
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Precigen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PGEN news & analysis

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

Zacks Investment Research · 14 Sept 2026positive

Precigen's stock has risen 43% over the past three months, with early sales of its product Papzimeos proving strong. The company's European expansion and advancing pipeline are cited as factors that could shape its future growth outlook.

Why it matters — PGEN watchers would want to track the momentum behind Papzimeos sales, along with European expansion and pipeline developments, as these are key drivers influencing the company's growth trajectory.

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Zacks Investment Research · 10 Sept 2026positive

Precigen's product Papzimeos is fueling company growth, with sales more than doubling sequentially in the second quarter and demand continuing to rise through 2026. The article examines whether Papzimeos can sustain Precigen's growth for the remainder of 2026.

Why it matters — A PGEN watcher would care because Papzimeos appears to be a key growth driver behind Precigen's recent revenue momentum and projected demand.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research · 27 Aug 2026neutral

Zacks Investment Research published an Industry Outlook article highlighting Halozyme, Repligen, Iovance, Arcutis and Precigen. The piece lists Precigen among the companies featured in the industry review.

Why it matters — A PGEN watcher would care because the company's inclusion in a Zacks industry overview draws analyst and investor attention to Precigen within the broader biotech sector.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Zacks Investment Research · 26 Aug 2026positive

Zacks Investment Research highlighted Precigen (PGEN) among five biotech stocks well-positioned in the Biomedical and Genetics industry, citing its strong portfolio and solid pipeline progress as supportive factors amid an uncertain macroeconomic environment and anticipated momentum from new drug approvals.

Why it matters — PGEN watchers would care because the piece singles out the company's pipeline progress and portfolio strength as reasons it is positioned favorably within the volatile biotech sector.

Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

Accesswire · 25 Aug 2026positive

Precigen reported a strong second quarter, with its new drug PAPZIMEOS (zopapogene imadenovec-drba) generating $53.1 million in net product revenue—more than double the prior quarter—and helping the company achieve quarterly profitability. The results also validate the company's AdenoVerse therapeutic platform and its potential in HPV-associated cancers, while PRGN-2009 advances in HPV-driven cancers.

Why it matters — The strong commercial traction of the first FDA-approved therapy for RRP and the validation of the AdenoVerse platform signal growing value for Precigen watchers.

FAQ

Frequently asked questions about PGEN stock

What is the PGEN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Precigen, Inc. have a median 12-month price target of $15, with estimates ranging from $11 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PGEN stock a buy right now?

Of the 3 analysts covering Precigen, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precigen, Inc. 83 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PGEN?

As at 19 Sept 2026, Precigen, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (100 of 100).

Will PGEN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +86.4% from the last close, and Ticker Nerd's factor model ranks Precigen, Inc. 83 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PGEN stock forecast for 2030?

No analyst covering Precigen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $18 over the next 12 months.

How has PGEN stock performed over the past year?

Precigen, Inc. returned +104.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Precigen, Inc. do?

Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases.

What is the latest news on PGEN?

The most recent item we track (Zacks Investment Research, 14 Sept 2026): "Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?". Precigen's stock has risen 43% over the past three months, with early sales of its product Papzimeos proving strong. The company's European expansion and advancing pipeline are cited as factors that could shape its future growth outlook.

Company

About Precigen, Inc.

Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases. The company applies gene and cell therapy platforms to create targeted programs in immuno-oncology, autoimmune disorders, and infectious diseases. Its work centers on advancing innovative therapeutic candidates and related research tools that support discovery, preclinical development, and clinical development. Precigen also operates through business segments that include biopharmaceutical activities and specialized research-model services, giving it a broad presence across therapeutic development and life-science applications. Headquartered in Germantown, Maryland, Precigen serves as a clinical-stage innovator in the biotechnology sector, with an emphasis on translating proprietary technology platforms into potential treatments for patients with unmet medical needs.

CEO Dr. Helen Sabzevari MPH, Ph.D. · 160 employees · United States · https://precigen.com